Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer

NCT05974059 | Unknown Phase 2

• 1 other identifier: AK104-IIT-C-N1-0036
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

The efficacy and safety of combination with Cadonilimab and CapeOX Regimen for neoadjuvant treatment of resectable locally advanced adenocarcinoma of the gastro-esophageal junction.

Conditions

Locally Advanced Unresectable Gastric Adenocarcinoma

Keywords

Resectable locally advanced adenocarcinoma of the gastro-esophageal junction

Outcome Measures

Primary Outcomes (1)

• Pathologic complete remission rate (PCR)

  Pathological complete response (pCR) rate is defined as the proportion of participants whose tumor in the stomach and lymph node completely disappeared, as determined by a pathologist.

  up to 1 years

Secondary Outcomes (5)

• 3-year disease-free survival rate of 3year (DFS)

  up to 3 years

• Major pathological response rate (MPR)

  up to 1 years

• Objective response rate(ORR)

  up to 3 years

• Disease Control Rate (DCR)

  up to 3 years

• Adverse Events（AEs）

  up to 3 years

Study Arms (1)

Cadonilimab

EXPERIMENTAL

10 mg/kg, d1, Q3W;

Drug: Oxaliplatin; Drug: Capecitabine; Drug: Cadonilimab

Interventions

Oxaliplatin DRUG

Preoperative treatment：130mg/m2，iv, 2h，d1，Q3W; Postoperative treatment：130mg/m2，iv, 2h，d1，Q3W;

Cadonilimab

Capecitabine DRUG

Preoperative treatment：1000 mg /m2, PO，bid d1-14，Q3W； Postoperative treatment：1000 mg /m2, PO，bid. d1-14，Q3W；

Cadonilimab

Cadonilimab DRUG

Cadonilimab 10 mg/kg, d1, Q3W

Cadonilimab

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female, 18 years ≤ age ≤ 75 years;
• ECOG score 0-1;
• Histologically confirmed gastric adenocarcinoma or adenocarcinoma of the gastroesophageal junction.
• c stageII, III(T1-4a/N+ M0, T3-4a/N-M0, AJCC 8th edition of gastric cancer cTNM stage) were performed according to enhanced CT/MRI examination (combined with ultrasonic gastroscopy and diagnostic laparoscopy if necessary).
• The study site and the operator can complete radical dissection of D2 lymph nodes (the number of examined lymph nodes must be at least 15 to ensure the operation quality), and R0 resection;
• Physical condition and organ function allow for larger abdominal surgery;
• It has adequate organ and bone marrow functions and is defined as follows:
• )Blood routine test: absolute neutrophil count (ANC) ≥1.5×109/L; Platelet count(PLT)≥100×109/L; Hemoglobin (HGB)≥9.0 g/dL; 2)Liver function: Total serum bilirubin (TBIL) ≤1.5×upper limit of normal (ULN) is required for patients without liver metastasis. alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5\*ULN; 3)Renal function: creatinine clearance rate (Ccr)≥50 mL/min (calculated by Cockcroft/Gault formula); a Female: Ccr= (140-years) x Body Weight (kg) x 0.85 72 x serum creatinine (mg/dL) b Males: Ccr= (140-years) x Weight (kg) x 1.00 72 x serum creatinine (mg/dL) 4) Adequate coagulation, defined as international normalized ratio (INR) or prothrombin time (PT) ≤1.5 times ULN; If the subject is receiving anticoagulant therapy, as long as the PT is within the intended range of the anticoagulant; 8 Left ventricular ejection fraction (LVEF)≥50% confirmed by echocardiography; 9 Agree and be able to comply with the protocol during the study; 10 Provide written informed consent prior to entering study screening and the patient is aware that she can withdraw from the study at any time during the study without loss; 11 Consent to provide blood and histological specimens

You may not qualify if:

• Complication of upper gastrointestinal tract obstruction/hemorrhage or digestive dysfunction or malabsorption syndrome;
• Concomitant severe uncontrolled concurrent infection or other serious uncontrolled concomitant disease, moderate or severe renal injury;
• Prior anti-tumor therapy, including chemotherapy, radiotherapy, targeted therapy or immunotherapy;
• Other malignancies (except basal or squamous cell carcinoma, superficial bladder cancer, cervical carcinoma in situ or breast cancer) in the past 5 years;
• Uncontrolled pleural effusion, pericardial effusion or ascites;
• Serious cardiovascular disease such as symptomatic coronary heart disease, congestive heart failure ≥Grade II, uncontrolled arrhythmia, myocardial infarction within 12 months prior to enrollment;
• Allergic reaction to the drugs used in this study;
• Use of steroids or other systemic immunosuppressive therapy 14 days prior to enrollment;
• Patients receiving study medication within 4 weeks prior to enrollment (participating in other clinical trials);
• Active autoimmune diseases;
• Medical history of primary immunodeficiency;
• Immunosuppressive medications were used within 4 weeks prior to the first dose of study treatment, excluding nasal spray, inhaled or other local corticosteroids or physiological doses of systemic corticosteroids (i.e. not more than 10 mg/day prednisone or equivalent dose of other corticosteroids), or the use of hormones to prevent contrast agent allergy;
• Receiving an attenuated live vaccine within 4 weeks prior to the first dose of study treatment or scheduled for the duration of the study;
• Known active tuberculosis;
• Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation;

Sponsors & Collaborators

• Tianjin Medical University Cancer Institute and Hospital: lead

Study Sites (1)

Xuewei Ding

Tianjin, Tianjin Municipality, 300308, China

Location

MeSH Terms

Interventions

Oxaliplatin; Capecitabine

Intervention Hierarchy (Ancestors)

Coordination Complexes; Organic Chemicals; Deoxycytidine; Cytidine; Pyrimidine Nucleosides; Pyrimidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Fluorouracil; Uracil; Pyrimidinones; Deoxyribonucleosides; Nucleosides; Nucleic Acids, Nucleotides, and Nucleosides

Study Officials

• Xuewei Ding, MD

  Tianjin Cancer Hospital Airport Hospital

  STUDY DIRECTOR

Central Study Contacts

Xuewei Ding, MD

CONTACT

18622220158; xding@tmu.edu.cn

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 24, 2023
• First Posted: August 3, 2023
• Study Start: August 1, 2023
• Primary Completion: August 1, 2024
• Study Completion: August 1, 2024
• Last Updated: August 3, 2023

Record last verified: 2023-07

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)